The Bottom Line

Toxic epidermal necrolysis (TEN) is the most severe form of drug-induced skin reaction — a life-threatening emergency where more than 30% of the skin surface blisters and peels off, similar to a severe burn. TEN has a mortality rate of 25-35% and requires immediate ICU or burn unit hospitalization. It is on the same disease spectrum as Stevens-Johnson Syndrome (SJS), differing only in the extent of skin involvement. The same medications cause TEN as SJS, and the same genetic risk factors apply.

What Is Toxic Epidermal Necrolysis (TEN)?

Toxic epidermal necrolysis is the most severe form of a spectrum of drug-induced skin reactions that includes Stevens-Johnson Syndrome (SJS). The classification is based on the percentage of body surface area (BSA) with skin detachment: SJS affects less than 10% BSA, SJS-TEN overlap affects 10-30%, and TEN affects more than 30% BSA. When over 30% of the skin blisters and separates — exposing the raw, vulnerable dermis beneath — the body faces catastrophic fluid loss, infection risk, and organ failure similar to a massive burn.

TEN affects approximately 0.4-1.2 people per million per year. Despite its rarity, it is one of the deadliest dermatologic emergencies. The SCORTEN scoring system predicts mortality based on factors like age, extent of detachment, and organ involvement — scores of 5 or higher carry mortality rates exceeding 90%.

Signs and Symptoms of TEN

Prodromal phase (1-3 days before skin involvement): High fever (often 39-40°C/102-104°F), severe malaise and body aches, painful skin (the skin feels burning or tender before any visible changes — a critical early warning), sore throat and difficulty swallowing, and eye burning and redness.

Acute phase:

  • Rapidly spreading dark red or purple macules (flat spots) across the trunk and face
  • Confluent (merging) areas of skin erythema that become tender and dusky
  • Large, flaccid blisters that rupture easily, leaving raw, weeping skin
  • Sheets of epidermis separate and peel off with minimal pressure (positive Nikolsky sign)
  • The detached skin can be rolled back like wet tissue paper
  • Exposed dermis is red, raw, and extremely painful
  • Mucous membrane involvement in over 90%: severe oral erosions (inability to eat), ocular involvement (risk of permanent corneal damage), and genital erosions

Systemic complications: Massive fluid and electrolyte loss through denuded skin, high risk of sepsis (the skin barrier is lost), acute kidney injury, respiratory failure (if airway mucosa is involved), and multi-organ failure.

What Causes TEN?

TEN has the same causes as SJS — medications are responsible in over 80% of cases. The same high-risk drugs apply: sulfonamide antibiotics, aromatic anticonvulsants (carbamazepine, phenytoin, lamotrigine), allopurinol, oxicam NSAIDs, and nevirapine. The same genetic risk factors (HLA-B*5801 for allopurinol, HLA-B*1502 for carbamazepine) predict risk.

The difference between SJS and TEN is not the cause but the severity of the immune response. Why some patients develop limited SJS while others progress to full TEN with the same drug is not fully understood but likely relates to the intensity of the cytotoxic T-cell response and the extent of Fas-FasL mediated keratinocyte apoptosis (programmed cell death of skin cells).

Treatment — TEN Is a Medical Emergency

Immediate actions (before hospital):

  1. STOP the suspected medication immediately
  2. Call 911 — TEN requires burn unit or ICU admission
  3. Do not apply ice, creams, or ointments to the skin
  4. Keep the patient warm (massive heat loss occurs through denuded skin)

Hospital management (burn unit/ICU):

  • Wound care: Non-adherent dressings, biologic dressings, or xenografts (pig skin) over denuded areas — similar to burn management
  • Fluid resuscitation: Aggressive IV fluids to replace losses through denuded skin (often using burn resuscitation formulas)
  • Temperature regulation: Ambient temperature raised to 30-32°C to prevent hypothermia
  • Nutrition: Early enteral feeding (through a nasogastric tube if oral intake is impossible) to support healing
  • Pain management: Often requires IV opioids — exposed dermis is extremely painful
  • Infection prevention: Strict aseptic technique, wound cultures, early treatment of sepsis
  • Ophthalmology: Daily eye care — lubricating drops, membrane removal, and monitoring. Eye complications are the most common long-term morbidity of TEN

Specific therapies: Cyclosporine (3-5 mg/kg/day) has the strongest emerging evidence for reducing mortality when started early. IVIG (intravenous immunoglobulin) is used at some centers. Systemic corticosteroids remain controversial. Etanercept (anti-TNF) has shown promise in small studies.

Recovery: Skin regrowth occurs over 2-4 weeks from surviving epidermal stem cells. Complete recovery takes months. Survivors may face chronic complications including dry eyes and vision problems (up to 75% of TEN survivors), skin pigmentation changes, nail loss or deformity, scarring of mucous membranes and genitalia, chronic pain, and significant psychological trauma.

When to Seek Emergency Care

TEN is an absolute medical emergency. Seek emergency care immediately if you or someone develops widespread painful, tender skin with redness that is rapidly spreading, large blisters or sheets of skin peeling off, combined fever plus mouth sores plus skin pain — especially within 1-3 weeks of starting a new medication, or inability to eat or drink due to severe mouth erosions. Every hour of delay in stopping the causative drug and starting supportive care worsens the prognosis.

Frequently Asked Questions

What is the survival rate for TEN?

Overall TEN mortality is 25-35%, making it one of the deadliest dermatologic conditions. Mortality correlates with the extent of skin detachment: SJS (less than 10% detachment) has 1-5% mortality, while TEN with greater than 30% detachment has 25-35% mortality. Age over 70, cancer, and extensive mucosal involvement worsen prognosis. Early drug withdrawal and ICU/burn unit care significantly improve survival. The SCORTEN severity score predicts individual mortality risk.

How is TEN different from a severe burn?

TEN and severe burns present similarly (denuded skin, fluid loss, infection risk) and are managed in burn units with similar protocols. The key difference is the cause: TEN is caused by the immune system killing skin cells (autoimmune), while burns are caused by external heat or chemicals. TEN skin regenerates from surviving epidermal stem cells (since the dermis is intact), while deep burns destroy these cells. TEN patients generally recover skin faster than equivalent-area burn patients, but the systemic immune dysfunction in TEN adds its own complications.

Can TEN be prevented?

In some cases, yes — through pharmacogenomic testing. Testing for HLA-B*5801 before prescribing allopurinol and HLA-B*1502 before prescribing carbamazepine to at-risk populations can prevent TEN in patients who carry these high-risk alleles. For other drug-TEN associations where genetic testing isn't yet available, vigilance during the first 8 weeks of high-risk medications — with immediate drug discontinuation at the first sign of reaction — is the best prevention strategy.

What happens to TEN survivors long-term?

Many TEN survivors face chronic health challenges: up to 75% have persistent dry eye disease requiring ongoing ophthalmologic care, some develop cicatricial (scarring) changes of the eyes, mouth, or genitalia, skin may heal with permanent pigmentation changes, nails may not regrow normally, and post-traumatic stress disorder is common. Comprehensive long-term follow-up with dermatology, ophthalmology, and psychology/psychiatry is recommended for all TEN survivors.

References

  1. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis. J Am Acad Dermatol. 2013;69(2):173.e1-173.e13.
  2. Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149-153.
  3. Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010;5:39.
  4. Zimmermann S, Sekula P, Venhoff M, et al. Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 2017;153(6):514-522.

Trusted Resources

TEN is a medical emergency. If you suspect TEN — stop the medication, call 911, and get to a hospital immediately. Minutes matter.